Eli Lilly's $3 BILLION Greenhouse Bet: Is Hydroponics the Next Pharma Frontier?
About this episode
Host Dr. Russell Sharp discusses Eli Lilly's recent purchase of a greenhouse site in Katwijk, Netherlands, and explores possible links to botanical sourcing and GLP‑1 weight‑loss drugs. He outlines how the $3 billion investment raises questions about future use, including pharmaceutical manufacturing, botanical ingredients, and impacts on horticulture.
The episode also touches on historical examples of plant‑derived medicines, the Nagoya Protocol on sharing benefits from genetic resources, and the wider implications for food demand and greenhouse agriculture. Tune in to hear the latest developments and what to watch for next.
https://eutrema.co.uk/shop/fertiliser/liquid-gold-unique-complete-fertiliser/
Wegovy (also semaglutide, approved for weight loss), Mounjaro and Zepbound (tirzepatide, a dual-action drug), and Saxenda (liraglutide)
Type 2 diabetes
Whoopi Goldberg, Charles Barkley, Amy Schumer, Serena Williams, Oprah Winfrey, and Elon Musk
Get every episode summarized
Each time Hydroponics Daily publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Hydroponics Daily
Insider Advice for Hydroponic Product Startups
Hydroponics Daily
UK Fertiliser Rules Could Wipe Out Small Hydro Brands — What You Need to Know
Hydroponics Daily
Taming Bitterness: How Hydroponics Could Create Milder Veggies
Hydroponics Daily
The Top 10 Most Poisonous Plants You Might Grow (but hey, "they're natural")
Hydroponics Daily